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Background
Antimalarial efficacy is dependent on administration of a
curative dose determined by the pharmacokinetic and
dynamic profile of the drug and the age and weight of the
patient. Optimal dosing strategies are frequently compro-
mised by pragmatic constraints resulting in patients
receiving a wide range of mg/kg dose. WWARN has estab-
lished a scientific research project aiming at pooling all
relevant patient level data from ACTs studies conducted
in malaria endemic areas. This study aimed at investigat-
ing the consequences of variance in dosing strategies of
key ACTs and their effect on clinical efficacy.
Methods
A systematic review generated a list of all antimalarial
clinical studies since 1960. Studies relevant to specific
pooled analyses were identified and principal investiga-
tors approached to contribute individual patient data,
which were then compiled into a standard format accord-
ing to a transparent Data Management and Statistical
Analysis Plan [1]. Data were collated for artemether-
lumefantrine (AL), artesunate-amodiaquine (AS+AQ)
and dihydroartemisinin-piperaquine (DHA+PQP) and
analysed separately according to an a priori analytical
plan to identify key risk factors for treatment efficacy,
recrudescence and new infection by day 28. Univariate
and multivariate risk factors were identified using Cox’s
regression model with frailty shared across the studies
to adjust for the differences between studies. Optimal
mg/ kg dosage of partner drugs which best predicted the
PCR adjusted recrudescence were explored using logrank
statistics for pre-defined weight/age categories.
Results
The WWARN repository currently contains over 75,000
individual patient records, 54% of which were treated with
ACTs. In the current pooled analysis there are 10,913
patients treated with AL, 6,073 with AS+AQ and 4,739
with DHA+PQP, constituting 45%, 40% and 35% of the
entire published data for these three drugs respectively.
For AL, significant multivariate risk factors for recrudes-
cence were baseline parasitaemia (log-scale) [AHR: 1.11,
95% CI: 1.00-1.23] and low weight category of 5-14 kg
[AHR: 2.08, 95% CI: 1.06-4.11]. However, the mg/ kg
dosage of lumefantrine was found not to be associated
with the recrudescent failures [P=0.83] in the final model.
Patient treated with non-fixed combination of AS+AQ
were at 2.8 fold [95% CI: 1.53-5.29] greater risk of recru-
descent failure compared to those treated with fixed dose
combination (FDC). For the non-fixed combination of AS
+AQ, logged baseline parasitaemia [AHR: 1.24, 95% CI:
1.07-1.45], low age category [age 1-5 years (AHR: 3.23,
95% CI: 0.90-11.94)] and the mg/kg amodiaquine dose
[AHR: 0.96, 95% CI: 0.93-1.01] were the major risk factors
for recrudescence in the final multivariate model. No risk
factors were significantly associated with failure with the
FDC. For DHA+PQP, patients in age group <12 years
[AHR: 4.13, 95% CI: 1.06-15.94] and patients receiving an
overall piperaquine dose of <48 mg/ kg [AHR: 1.69, 95%
CI: 0.95-3.02] were at greater risk of recrudescence.
Conclusions
Pooled analyses of diverse clinical studies are feasible using
standard algorithms and semi-automated processing and
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can provide new insights on risk factors of failure. Large
standardised datasets provide substantial power to explore
the impact of different dosing strategies and derive opti-
mal treatment protocols.
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